Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Selective antagonism of TRPA1 produces limited efficacy in models of inflammatory- and neuropathic-induced mechanical hypersensitivity in rats.

Lehto SG, Weyer AD, Youngblood BD, Zhang M, Yin R, Wang W, Teffera Y, Cooke M, Stucky CL, Schenkel L, Geuns-Meyer S, Moyer BD, Wild KD, Gavva NR.

Mol Pain. 2016 Nov 29;12. pii: 1744806916677761. Print 2016.

2.

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.

Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C.

J Pharmacol Exp Ther. 2016 Jan;356(1):223-31. doi: 10.1124/jpet.115.227793. Epub 2015 Nov 11.

PMID:
26559125
3.

AMG2850, a potent and selective TRPM8 antagonist, is not effective in rat models of inflammatory mechanical hypersensitivity and neuropathic tactile allodynia.

Lehto SG, Weyer AD, Zhang M, Youngblood BD, Wang J, Wang W, Kerstein PC, Davis C, Wild KD, Stucky CL, Gavva NR.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Apr;388(4):465-76. doi: 10.1007/s00210-015-1090-9. Epub 2015 Feb 10.

4.

Expression profile of nerve growth factor after muscle incision in the rat.

Wu C, Erickson MA, Xu J, Wild KD, Brennan TJ.

Anesthesiology. 2009 Jan;110(1):140-9. doi: 10.1097/ALN.0b013e318190bc84.

5.

Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance.

Wild KD, Bian D, Zhu D, Davis J, Bannon AW, Zhang TJ, Louis JC.

J Pharmacol Exp Ther. 2007 Jul;322(1):282-7. Epub 2007 Apr 12.

PMID:
17431136
6.

Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1.

Gavva NR, Tamir R, Klionsky L, Norman MH, Louis JC, Wild KD, Treanor JJ.

Mol Pharmacol. 2005 Dec;68(6):1524-33. Epub 2005 Aug 31.

PMID:
16135784
7.

AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties.

Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, Wang J, Zhu D, Vanderah TW, Porreca F, Doherty EM, Norman MH, Wild KD, Bannon AW, Louis JC, Treanor JJ.

J Pharmacol Exp Ther. 2005 Apr;313(1):474-84. Epub 2004 Dec 22.

PMID:
15615864
8.

2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor.

Scott MK, Ross TM, Lee DH, Wang HY, Shank RP, Wild KD, Davis CB, Crooke JJ, Potocki AC, Reitz AB.

Bioorg Med Chem. 2000 Jun;8(6):1383-91.

PMID:
10896115
9.

Galanin inhibits acetylcholine release from rat cerebral cortex via a pertussis toxin-sensitive G(i)protein.

Wang HY, Wild KD, Shank RP, Lee DH.

Neuropeptides. 1999 Jun;33(3):197-205.

PMID:
10657492
10.

Differentiation of receptor subtypes by thermodynamic analysis: application to opioid delta receptors.

Wild KD, Porreca F, Yamamura HI, Raffa RB.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12018-21.

11.

Antinociceptive actions of BW373U86 in the mouse.

Wild KD, McCormick J, Bilsky EJ, Vanderah T, McNutt RW, Chang KJ, Porreca F.

J Pharmacol Exp Ther. 1993 Nov;267(2):858-65.

PMID:
8246160
12.

Modulation of morphine antinociception by swim-stress in the mouse: involvement of supraspinal opioid delta-2 receptors.

Vanderah TW, Wild KD, Takemori AE, Sultana M, Portoghese PS, Bowen WD, Hruby VJ, Mosberg HI, Porreca F.

J Pharmacol Exp Ther. 1993 Oct;267(1):449-55.

PMID:
8229774
13.

Binding of BW 373U86, a non-peptidic delta opioid receptor agonist, is not regulated by guanine nucleotides and sodium.

Wild KD, Fang L, McNutt RW, Chang KJ, Toth G, Borsodi A, Yamamura HI, Porreca F.

Eur J Pharmacol. 1993 Aug 15;246(3):289-92.

PMID:
8223952
14.

Pseudoirreversible binding characteristics of [D-Ala2,Glu4]deltorphin and its Cys4 substituted derivative to delta-opioid receptors.

Wild KD, Horan PJ, Misicka A, Lipkowski A, Haaseth RC, Matsunaga TO, Hruby VJ, Toth G, Borsodi A, Yamamura HI, et al.

Eur J Pharmacol. 1993 Jun 15;246(1):25-31.

PMID:
8394818
15.

Agonist and antagonist profiles of [D-Ala2,Glu4]deltorphin and its [Cys4]- and [Ser4]-substituted derivatives: further evidence of opioid delta receptor multiplicity.

Horan PJ, Wild KD, Misicka A, Lipkowski A, Haaseth RC, Hruby VJ, Weber SJ, Davis TP, Yamamura HI, Porreca F.

J Pharmacol Exp Ther. 1993 May;265(2):896-902.

PMID:
8388462
16.

Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.

Horan PJ, Wild KD, Kazmierski WM, Ferguson R, Hruby VJ, Weber SJ, Davis TP, Fang L, Knapp RJ, Yamamura HI, et al.

Eur J Pharmacol. 1993 Mar 16;233(1):53-62.

PMID:
8386089
17.

Thermodynamic parameters for [D-Pen2,5]enkephalin at delta-opioid receptors in the mouse isolated vas deferens.

Raffa RB, Wild KD, Mosberg HI, Porreca F.

Eur J Pharmacol. 1993 Feb 15;244(3):231-8.

18.

Evidence for a single functional opioid delta receptor subtype in the mouse isolated vas deferens.

Wild KD, Carlisi VJ, Mosberg HI, Bowen WD, Portoghese PS, Sultana M, Takemori AE, Hruby VJ, Porreca F.

J Pharmacol Exp Ther. 1993 Feb;264(2):831-8.

PMID:
8382281
19.
20.

Cocaine place preference is blocked by the delta-opioid receptor antagonist, naltrindole.

Menkens K, Bilsky EJ, Wild KD, Portoghese PS, Reid LD, Porreca F.

Eur J Pharmacol. 1992 Aug 25;219(2):345-6.

PMID:
1425962
21.

Mediation of swim-stress antinociception by the opioid delta 2 receptor in the mouse.

Vanderah TW, Wild KD, Takemori AE, Sultana M, Portoghese PS, Bowen WD, Mosberg HI, Porreca F.

J Pharmacol Exp Ther. 1992 Jul;262(1):190-7.

PMID:
1320682
22.

Opioidergic, serotonergic, and dopaminergic manipulations and rats' intake of a sweetened alcoholic beverage.

Hubbell CL, Marglin SH, Spitalnic SJ, Abelson ML, Wild KD, Reid LD.

Alcohol. 1991 Sep-Oct;8(5):355-67.

PMID:
1797032
23.

Opioid delta receptor subtypes are associated with different potassium channels.

Wild KD, Vanderah T, Mosberg HI, Porreca F.

Eur J Pharmacol. 1991 Jan 25;193(1):135-6. No abstract available. Erratum in: Eur J Pharmacol 1991 Apr 3;195(3):415.

24.

Lack of irreversible antagonism of opioid & receptors by [D-ala2,Leu5,Cys6] enkephalin in the mouse isolated vas deferens preparation.

Wild KD, Jiang Q, Iannone M, Bowen W, Porreca F.

NIDA Res Monogr. 1990;105:402-3. No abstract available.

PMID:
1652085
25.

Chronically administered morphine, circadian cyclicity, and intake of an alcoholic beverage.

Choi HW, Wild KD, Hubbell CL, Reid LD.

Alcohol. 1990 Jan-Feb;7(1):7-10.

PMID:
2310507
26.
27.

PCP, THC, ethanol, and morphine and consumption of palatable solutions.

Milano WC, Wild KD, Hui YZ, Hubbell CL, Reid LD.

Pharmacol Biochem Behav. 1988 Dec;31(4):893-7.

PMID:
2855270
28.

Further studies of opioids and intake of sweetened alcoholic beverage.

Hubbell CL, Abelson ML, Wild KD, Neuman R, Reid LD.

Alcohol. 1988 Mar-Apr;5(2):141-6.

PMID:
2840095

Supplemental Content

Support Center